Hot Stock: Genta Incorporated (OTC: GNTA)

XCSFDHG46767FHJHJF

tdp2664 Epic Stock Picks The shares closed at $0.0157 on Monday with a fall of 63.40%. This steep fall should be attributed to the Company's announcement regarding the poor results of its 10 year long effort to achieve a clinically meaningful benefit for patients with melanoma. The shares traded at prices much below the prior 1 month range and have contributed in creating 52 week lowest price. On Monday the Company announced that overall survival for patients treated with Genasense®(oblimersen sodium) Injection plus chemotherapy in AGENDA, the Company’s Phase 3 trial of Genasense® in patients with advanced melanoma, did not bring significantly superior results as compared with patients treated with chemotherapy alone. AGENDA was known to be a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who had not previously received chemotherapy. As described in a prior randomized trial, AGENDA employed a biomarker to identify and define patients who might maximally benefit from such treatment. In the trial, median survival was 13.5 months in the Genasense group® as compared to 13.1 months in the chemotherapy-only group (P=0.73). The durable response rate (which means the proportion of patients who achieved a major objective response that persists at least 6 months) was 10.8% and 7.6%, respectively (P=0.32). According to Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer, they are quiet disappointed with this result, which has terminated their 10-year effort to achieve a clinically meaningful benefit for patients with melanoma. Moreover, he added that keeping these results in view, they plan to review the Company’s pipeline portfolio and provide further guidance in the near future. He also acknowledged that the Company is grateful for the tireless dedication of its employees and for the contributions of the many physicians, patients, and families who have worked to advance Genasense for cancer treatment. Genta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company is engaged in the identification, development and commercialization of drugs for the treatment of cancer and related diseases.